FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955121102> ?p ?o ?g. }

• W2955121102 abstract "7522 Background: Ibrutinib therapy is associated with an increased risk (~15%) of AF. An accurate risk assessment model for the development of AF in pts starting ibrutinib is not established, and outcomes after AF are not well described. Methods: An IRB approved retrospective review of CLL pts treated with ibrutinib at Mayo Clinic between Oct 2012 and Nov 2018 was conducted. Results: 299 pts were identified with a total of 565 years of ibrutinib exposure (Table). After a median follow-up of 24 months (range 0–70 months), 51 pts developed treatment-emergent AF (13 [25%] CTCAE 3 or higher). Our study assessed 3 clinical prediction models, the Framingham (Schanbel:Lancet 2009), Italian (Visentin:Blood 2018;132:3118), and Shanafelt (Shanafelt:Leuk Lymp; 2017) risk scores. Based on a lower Akaike information criteria, the Italian score was best able to predict risk of treatment emergent AF (2-year risk of AF with score 0 6%; 1-2 8%; 3-4 26%; 5+ 47%). Thirty (61%) pts were treated with medical therapy for AF (27 rate control; 2 rhythm control; 1 both). 16 (31%) pts underwent interventional therapy (3 AV node ablation; 11 cardioversion; and 2 pacemaker). Twelve (23%) pts temporarily held ibrutinib and resumed their original dose, 22 (43%) pts continued reduced dose ibrutinib and 11 (22%) continued their initial ibrutinib dose. Six (12%) pts permanently discontinued ibrutinib. Of 51 pts with treatment-emergent AF, 41 (80%) had a CHA 2 DS 2 -VASc score of ≥2 (41% received anticoagulation alone; 12% received antiplatelet therapy alone; 10% received both). No pt developed a thrombotic stroke after treatment-emergent AF. Two major bleeds, (1 GI and 1 intracranial) occurred, one in a pt on concomitant antiplatelet and anticoagulation therapy, and one in a pt receiving neither. The development of AF was associated with shorter event-free survival (HR 2.5, 95%CI 1.5-4.2, p<.001) and shorter overall survival (HR 3.5, 95%CI 2.0-6.3, p<.001). Conclusions: The Italian score was the best predictor of AF development in this cohort of ibrutinib treated pts. Although the vast majority of pts who develop AF after ibrutinib are able to continue therapy, the occurrence of AF appears to be associated with shorter EFS and OS. [Table: see text]" @default.
• W2955121102 created "2019-07-12" @default.
• W2955121102 creator A5002515721 @default.
• W2955121102 creator A5009747339 @default.
• W2955121102 creator A5033825180 @default.
• W2955121102 creator A5037323115 @default.
• W2955121102 creator A5045789519 @default.
• W2955121102 creator A5051752737 @default.
• W2955121102 creator A5051772970 @default.
• W2955121102 creator A5054196868 @default.
• W2955121102 creator A5054300127 @default.
• W2955121102 creator A5065682761 @default.
• W2955121102 creator A5067100969 @default.
• W2955121102 creator A5075005037 @default.
• W2955121102 creator A5077686486 @default.
• W2955121102 creator A5078869044 @default.
• W2955121102 creator A5087950597 @default.
• W2955121102 date "2019-05-20" @default.
• W2955121102 modified "2023-09-27" @default.
• W2955121102 title "Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes." @default.
• W2955121102 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.7522" @default.
• W2955121102 hasPublicationYear "2019" @default.
• W2955121102 type Work @default.
• W2955121102 sameAs 2955121102 @default.
• W2955121102 citedByCount "2" @default.
• W2955121102 countsByYear W29551211022020 @default.
• W2955121102 countsByYear W29551211022022 @default.
• W2955121102 crossrefType "journal-article" @default.
• W2955121102 hasAuthorship W2955121102A5002515721 @default.
• W2955121102 hasAuthorship W2955121102A5009747339 @default.
• W2955121102 hasAuthorship W2955121102A5033825180 @default.
• W2955121102 hasAuthorship W2955121102A5037323115 @default.
• W2955121102 hasAuthorship W2955121102A5045789519 @default.
• W2955121102 hasAuthorship W2955121102A5051752737 @default.
• W2955121102 hasAuthorship W2955121102A5051772970 @default.
• W2955121102 hasAuthorship W2955121102A5054196868 @default.
• W2955121102 hasAuthorship W2955121102A5054300127 @default.
• W2955121102 hasAuthorship W2955121102A5065682761 @default.
• W2955121102 hasAuthorship W2955121102A5067100969 @default.
• W2955121102 hasAuthorship W2955121102A5075005037 @default.
• W2955121102 hasAuthorship W2955121102A5077686486 @default.
• W2955121102 hasAuthorship W2955121102A5078869044 @default.
• W2955121102 hasAuthorship W2955121102A5087950597 @default.
• W2955121102 hasConcept C126322002 @default.
• W2955121102 hasConcept C143998085 @default.
• W2955121102 hasConcept C2777938653 @default.
• W2955121102 hasConcept C2778461978 @default.
• W2955121102 hasConcept C2779161974 @default.
• W2955121102 hasConcept C2779878957 @default.
• W2955121102 hasConcept C71924100 @default.
• W2955121102 hasConceptScore W2955121102C126322002 @default.
• W2955121102 hasConceptScore W2955121102C143998085 @default.
• W2955121102 hasConceptScore W2955121102C2777938653 @default.
• W2955121102 hasConceptScore W2955121102C2778461978 @default.
• W2955121102 hasConceptScore W2955121102C2779161974 @default.
• W2955121102 hasConceptScore W2955121102C2779878957 @default.
• W2955121102 hasConceptScore W2955121102C71924100 @default.
• W2955121102 hasLocation W29551211021 @default.
• W2955121102 hasOpenAccess W2955121102 @default.
• W2955121102 hasPrimaryLocation W29551211021 @default.
• W2955121102 hasRelatedWork W2573035975 @default.
• W2955121102 hasRelatedWork W2738203102 @default.
• W2955121102 hasRelatedWork W2739393823 @default.
• W2955121102 hasRelatedWork W2774223142 @default.
• W2955121102 hasRelatedWork W2782355857 @default.
• W2955121102 hasRelatedWork W2803967243 @default.
• W2955121102 hasRelatedWork W2888496958 @default.
• W2955121102 hasRelatedWork W2899118293 @default.
• W2955121102 hasRelatedWork W2900544116 @default.
• W2955121102 hasRelatedWork W2915676497 @default.
• W2955121102 hasRelatedWork W2944976872 @default.
• W2955121102 hasRelatedWork W2959821217 @default.
• W2955121102 hasRelatedWork W2981897797 @default.
• W2955121102 hasRelatedWork W2996304730 @default.
• W2955121102 hasRelatedWork W3049118620 @default.
• W2955121102 hasRelatedWork W3096007017 @default.
• W2955121102 hasRelatedWork W3105080374 @default.
• W2955121102 hasRelatedWork W3114567163 @default.
• W2955121102 hasRelatedWork W3118684185 @default.
• W2955121102 hasRelatedWork W3179993901 @default.
• W2955121102 isParatext "false" @default.
• W2955121102 isRetracted "false" @default.
• W2955121102 magId "2955121102" @default.
• W2955121102 workType "article" @default.